Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- BMS Mulls CAR-T Manufacturing in Japan, Definitive Plans Expected by Year-End
February 14, 2023
- Asahi Kasei to Push Teribone Auto-Injector, but AG Remains an Option: President
February 13, 2023
- Xocova’s Serious Side Effect Cases Total 5: Shionogi
February 13, 2023
- Kyowa Kirin Has No Plans to Launch Biosame of G-Lasta: President
February 10, 2023
- Fuji Pharma/M3’s Dysmenorrhea Drug Hits Main PIII Goal; 2024 Launch Eyed
February 10, 2023
- Spikevax Filed for Kids Aged 6 to 11 in Japan: Moderna
February 10, 2023
- Takeda Wraps Up Acquisition of Nimbus’ TYK2 Immune Therapy
February 10, 2023
- Sumitomo Sees Sales Force as Asset to Lure Collabs; Rep Cut Not in the Cards though Trulicity Deal Ended
February 9, 2023
- Santen’s Glaucoma Med Tapcom Accepted for Review in China
February 9, 2023
- Masao Hirokawa Named Next President of Fujifilm Kyowa Kirin Biologics
February 9, 2023
- Mitsubishi Tanabe Incurs 33 Billion Yen Operating Loss on Medicago Shutdown
February 8, 2023
- Kyowa Kirin’s Crysvita Crosses Blockbuster Line: 2022 Earnings
February 8, 2023
- Takhzyro Adds Pediatric Indication in US: Takeda
February 8, 2023
- Daiichi Sankyo Espha’s Nexium Generic Hits Japan Market
February 8, 2023
- Japan Ethical Drug Sales Surge 5.8% in December: Crecon
February 8, 2023
- CSL Behring Soon to Launch Home Delivery Service for Hemophilia Therapies
February 8, 2023
- ASKA, Japan Biotech Strike R&D Deal to Create VHH Therapies in OB-GYN Field
February 8, 2023
- Eisai Alzheimer’s Chief Says Lecanemab US Sales “Ahead of Expectations”
February 7, 2023
- Next Astellas CEO Says Weathering Xtandi Cliff Is His Biggest Mission
February 7, 2023
- Teijin Pharma Picks R&D Chief Taneda for President from April
February 7, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…